Aurobindo Pharma receives USFDA approval to market potassium chloride

Aurobindo Pharma Ltd has received USFDA approval to market potassium chloride tablets of 600 mg and 750 mg in the US market. The tablet, a generic version of Upsher-Smith’s Klor-Con extended release tablets is likely to be launched next month. The drug – potassium chloride tablets are used for treating hypokalemia, a condition wherein there is a drop in the potassium-level in the blood.

According to market estimates, the drug has an estimated market size of USD 60 million for 12 months ending October 2018.

Company Profile : Aurobindo Pharma Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*